First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study was designed to find the safest and most effective dose of a combination of two
chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with
extensive disease small cell lung cancer.